Individuals Stopping Anti-Obesity Medications Regain Pounds at a Quadrupled Rate Than Dieters

A recent study reveals that individuals who come off popular slimming jabs like Wegovy and Mounjaro can put back on lost weight much more quickly than those who halt traditional diet and exercise plans.

Findings released in a prominent medical journal points out that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.

"People buying such medications should be aware of the danger of quick weight regain when the treatment ends," warns researcher Dr. Susan Jebb.

Such speed of recovery suggests a return to pre-treatment mass in about one and a half years.

Comparing Approaches

The analysis, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.

Scientists emphasize that people who shed pounds through lifestyle changes alone generally experience a slower weight regain—around 0.1 kg a month—after stopping.

Explaining the Fast Rebound

Nutrition scientists suggest the mode of action of the drugs explains the accelerated weight return.

These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Artificially providing the hormone levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.

"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating far more likely."

An Ongoing Disease?

Medical guidelines recommend the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.

Professionals say that, due to the significant potential of weight regain, the treatment should be considered long-term.

This perspective is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like high blood pressure.

Patient Experiences

People who have discontinued the medication report a intense return of hunger.

"I experienced a trigger activating and you're instantly extremely hungry," described a patient.

The struggle is compounded if users have not established permanent lifestyle or habit changes during treatment.

Growing Interest

Recent estimates indicate that a significant number of people in the UK have used these injections in the past year, with demand continuing to grow.

• Adoption is more common among females than males.
• The middle-aged demographic shows the highest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

Finally, researchers caution that while these medications are effective agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on combined behavioural support.